BO

Boiron SAPAR Boiron Stock Report

Last reporting period 30 Jun, 2024

Updated 08 Nov, 2024

Last price

Market cap $B

0.609

Micro

Exchange

XPAR - Euronext Paris

BOI.PA Stock Analysis

BO

Neutral

Based on Eyestock quantitative analysis, BOI.PA`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

66/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-16.4 %

Overvalued

Market cap $B

0.609

Dividend yield

32.57 %

Shares outstanding

17.368 B

Boiron SA engages in the manufacturing and selling homeopathic medicines. The company is headquartered in Rontalon, Auvergne-Rhone-Alpes. The firm develops, manufactures and markets single homeopathic medicines and drugs which are in the form of tablets, syrups, single-dose liquids and ointments. The company also produces medicines based on trace elements, phytotherapy remedies, food supplements, as well as health and beauty care products. In addition, the Company owns a research center, which works for the development of homeopathy within the world of medicine. Boiron SA operates through a number of subsidiaries, which are based in Italy, Spain, Belgium, the Czech Republic, Slovakia, Russia, Romania, Poland, Hungary, the United States, Canada and Brazil, among others.

View Section: Eyestock Rating